achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA HANGZHOU, China, March 4, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...

The biopharmaceutical company announced an exclusive license for a portfolio of antibody-drug conjugates (ADCs) in collaboration with WuXi Biologics and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. The ...

Aadi Bioscience, Inc. ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the ...

The biopharmaceutical company announced an exclusive license for a portfolio of antibody-drug conjugates (ADCs) in collaboration with WuXi Biologics and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. The ...

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level ...

WuXi has disputed an early WBJ report saying construction at the Worcester site has stopped, although the company declined to ...

WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA (pDNA). The worldwide market for microbial-derived ...

Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 11, 2025 /PRNewswire/ ...